Neximmune announces research collaboration with rutgers, the state university of new jersey, related to neuroendocrine tumor targets

Gaithersburg, md., feb. 01, 2022 (globe newswire) -- neximmune, inc. (nasdaq: nexi), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells, today announced a collaboration with rutgers, the state university of new jersey. the collaboration will focus on the discovery and development of novel therapies targeting immune checkpoint proteins for the treatment of neuroendocrine tumors and other cancers. dr. steven k. libutti, director of rutgers cancer institute of new jersey, vice chancellor of cancer programs, rutgers biomedical and health sciences, and senior vice president of oncology services, rwjbarnabas health, will be the principal investigator.
NEXI Ratings Summary
NEXI Quant Ranking